梯瓦制药ADS按1:1转换为普通股并在纽交所以同一代码TEVA交易，属无现金流变化的证券形式切换

----- d503082d8k.htm -----
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
September 14, 2026
TEVA PHARMACEUTICAL INDUSTRIES LIMITED
(Exact name of registrant as specified in its charter)
Israel
001-16174
Not Applicable
(State or other jurisdiction
of Incorporation)
(Commission
File Number)
(IRS Employer
Identification Number)
400 Interpace Parkway, #3
Parsippany
New Jersey
,
07054
,
USA
(Address of Principal Executive Offices, including Zip Code)
+1-
973
-
658-0301
(Registrant’s Telephone Number, including Area Code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
☐
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
☐
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
Symbol(s)
Name of each exchange
on which registered
Ordinary Share
TEVA
New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this chapter).
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01.
Results of Operations and Financial Condition.
On September 14, 2026, Teva Pharmaceutical Industries Ltd. (the “
Company
”) began trading its ordinary shares on the New York Stock Exchange, in lieu of its American depositary shares (“
ADSs
”), under the same ticker symbol under which the ADSs previously traded, “TEVA”. Also on September 14, 2026, the Company’s ADS program terminated, with each ADS exchanged for one ordinary share. The Company’s ordinary shares continue to trade on the Tel Aviv Stock Exchange under the same symbol, “TEVA”. Additional information is available on the investor relations section of the Company’s website, available at ir.tevapharm.com.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Date: September 14, 2026
By:
/s/ Eli Kalif
Eli Kalif
Executive Vice President, Chief Financial Officer